A randomised comparison of <scp>FLAG‐Ida</scp> versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the <scp>UK NCRI AML17</scp> trial-Reference-Cited by-同舟云学术

A randomised comparison of FLAG‐Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the UK NCRI AML17 trial

Published:2022-04-06 Issue:3 Volume:198 Page:528-534
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Russell Nigel H.¹^ORCID,Hills Robert K.²^ORCID,Kjeldsen Lars³,Clark Richard E.⁴,Ali Sahra⁵,Cahalin Paul⁶,Thomas Ian F.⁷,Burnett Alan K.⁸

Affiliation:

1. Department of Haematology Guy's Hospital London UK

2. Nuffield Department of Population Health University of Oxford Oxford UK

3. Department of Haematology Rigshospitalet Copenhagen Denmark

4. Department of Molecular and Clinical Cancer Medicine University of Liverpool UK

5. Department of Haematology Castle Hill Hospital Hull UK

6. Department of Haematology Blackpool Victoria Hospital Blackpool UK

7. Centre for Trials Research Cardiff University Cardiff UK

8. Paul O'Gorman Leukaemia Centre University of Glasgow Glasgow UK

Funder

Cancer Research UK

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.18195

Reference15 articles.

1. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

2. International Randomized Phase III Study of Elacytarabine Versus Investigator Choice in Patients With Relapsed/Refractory Acute Myeloid Leukemia

3. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study

4. Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML

5. Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk Stratification in Older Intensively Treated Patients With AML;Journal of Clinical Oncology;2024-09-04

2. FLAG-Ida’ya Karşı FLAG-Dauno: Relaps/Refrakter Akut Lösemi Olgularında Bursa Uludağ Üniversitesi Deneyimi;Uludağ Üniversitesi Tıp Fakültesi Dergisi;2024-05-17

3. Non-Immunotherapy Approaches for Relapsed or Refractory AML: An Update for 2024;Acta Haematologica;2023-10-31